췌장 내분비 종양 시장 : 시장 규모, 점유율 및 성장 분석 - 종양 유형별, 기능성 종양 유형별, 치료법별, 진단 방법별, 최종사용자별, 환자 유형별, 지역별 업계 예측(-2026-2033년)

Global pancreatic endocrine tumor market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.08 Billion in 2025 to USD 4.94 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The global pancreatic endocrine tumor (PET) market encompasses the commercial landscape for diagnostics, therapeutics, and supportive care related to neuroendocrine neoplasms originating in the pancreas. With its increasing prevalence and the significant costs associated with late-stage treatment, this market is gaining prominence. The growth is primarily driven by advancements in peptide receptor radionuclide therapy (PRRT), which integrates diagnostic imaging with targeted radiation therapy. As clinicians demonstrate improved patient outcomes, payers become more inclined to reimburse these innovative treatments, prompting manufacturers to increase production and develop companion diagnostics. Furthermore, AI-driven precision medicine is revolutionizing the market by enhancing data utilization, enabling quicker identification of tumor subtypes, and fostering tailored treatment regimens, ultimately attracting investment and facilitating market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global pancreatic endocrine tumor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global pancreatic endocrine tumor Market Segments Analysis

The global pancreatic endocrine tumor market is segmented based on tumor type, functioning tumor type, treatment type, diagnosis type, end user, patient type, and region. By tumor type, the market is categorized into functioning pancreatic endocrine tumors and non-functioning pancreatic endocrine tumors. Based on functioning tumor type, the market is segmented into insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma, and others. Based on treatment type, the market is divided into surgery, targeted therapy, somatostatin analog therapy, chemotherapy, peptide receptor radionuclide therapy (PRRT), and other treatment options. By diagnosis type, the market comprises imaging tests, biochemical tests, histopathology & biopsy, and molecular diagnostics. Based on end user, the market is segmented into hospitals, cancer treatment centers, specialty endocrinology clinics, and academic & research institutes. By patient type, the market is classified into adult, geriatric, and pediatric populations. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global pancreatic endocrine tumor Market

The global pancreatic endocrine tumor market is significantly driven by advancements in molecular diagnostics that enhance the early detection of these tumors, allowing healthcare professionals to identify the disease while curative options remain viable. Improved sensitivity and specificity through genetic and imaging markers reduce diagnostic uncertainty, enabling faster treatment decisions. This heightened diagnostic accuracy encourages clinicians to adopt innovative therapeutic protocols and increases the utilization of specialized procedures as well as companion drugs. Consequently, there is a growing demand for diagnostic platforms, targeted therapies, and supportive services, which fuels ongoing growth within the market for pancreatic endocrine tumors.

Restraints in the Global pancreatic endocrine tumor Market

The global pancreatic endocrine tumor market faces significant restraints primarily due to the high costs associated with targeted therapies. These expensive treatment options often deter widespread adoption, especially in healthcare systems operating under strict reimbursement constraints. As hospitals and patients encounter substantial financial burdens from costly biologics and precision medicines, this leads to apprehensive prescribing practices. The financial pressure can also hinder the development of advanced treatment facilities, prompting clinicians to revert to more conventional and less effective therapies. Furthermore, insurers may impose prior authorization requirements, resulting in delays in initiating treatment and fostering reluctance among providers, ultimately stifling market growth.

Market Trends of the Global pancreatic endocrine tumor Market

The global pancreatic endocrine tumor market is witnessing a significant trend toward the integration of precision immunotherapy, revolutionizing treatment approaches. By combining checkpoint inhibitors with molecular profiling, clinicians are optimizing therapies tailored to individual tumor antigens, effectively addressing the complexities of this disease. This innovative strategy not only enhances patient outcomes through personalized regimens but also reduces off-target toxicity, resulting in durable responses, especially among patients previously unresponsive to traditional chemotherapy. Collaborative efforts between biotech firms and academic institutions are accelerating pipeline development, positioning immunotherapy as a critical component of future therapeutic platforms, thereby attracting increased investment, expanding clinical trial networks, and improving patient access across the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Pancreatic Endocrine Tumor Market Size by Tumor Type & CAGR (2026-2033)

• Market Overview
• Functioning Pancreatic Endocrine Tumors
• Non-Functioning Pancreatic Endocrine Tumors

Global Pancreatic Endocrine Tumor Market Size by Functioning Tumor Type & CAGR (2026-2033)

• Market Overview
• Insulinoma
• Gastrinoma
• Glucagonoma
• VIPoma
• Somatostatinoma
• Others

Global Pancreatic Endocrine Tumor Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Surgery
• Targeted Therapy
• Somatostatin Analog Therapy
• Chemotherapy
• Peptide Receptor Radionuclide Therapy (PRRT)
• Others

Global Pancreatic Endocrine Tumor Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Imaging Tests
• Biochemical Tests
• Histopathology & Biopsy
• Molecular Diagnostics

Global Pancreatic Endocrine Tumor Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Specialty Endocrinology Clinics
• Academic & Research Institutes

Global Pancreatic Endocrine Tumor Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Adult
• Geriatric
• Pediatric

Global Pancreatic Endocrine Tumor Market Size & CAGR (2026-2033)

• North America (Tumor Type, Functioning Tumor Type, Treatment Type, Diagnosis Type, End User, Patient Type)
  • US
  • Canada
• Europe (Tumor Type, Functioning Tumor Type, Treatment Type, Diagnosis Type, End User, Patient Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Type, Functioning Tumor Type, Treatment Type, Diagnosis Type, End User, Patient Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Type, Functioning Tumor Type, Treatment Type, Diagnosis Type, End User, Patient Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Type, Functioning Tumor Type, Treatment Type, Diagnosis Type, End User, Patient Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITM SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crinetics Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchmed (China) Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Molecular Partners AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncoinvent AS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• POINT Biopharma Global Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations